Consistent with our data, treatment with a combination of 5′-Aza and erlotinib, which antagonizes ABCB1, is synergistically cytotoxic in several AML cell lines, including SKM1, MOLM-13, HL-60, and MV4-11 (12). Here, ABCB1 is linked to acute myeloid leukemia.